Genentech/Xoma Raptiva Clears FDA, Priced At 25% Discount to Amevive
Executive Summary
Genentech/Xoma's psoriasis therapy Raptiva will be available by Thanksgiving at a 25% discount to a full year of Biogen's intramuscular injection formulation of Amevive
You may also be interested in...
Genentech Aborts Raptiva Amidst Reports Of Fatal Brain Infection
Risk management program couldn't save psoriasis drug. Decision is final, firm says.
Can A REMS Save Raptiva? Tysabri-Style Program Would Mean Restrictions
Ongoing discussions about a risk management plan for Genentech's Raptiva (efalizumab) may provide an avenue to maintain the psoriasis drug's commercial viability, despite its safety problems
Can A REMS Save Raptiva? Tysabri-Style Program Would Mean Restrictions
Ongoing discussions about a risk management plan for Genentech's Raptiva (efalizumab) may provide an avenue to maintain the psoriasis drug's commercial viability, despite its safety problems